Author(s):
Kote Rupali B, Wakchaure Rutuja K, Uchade Komal K, Lokhande Poonam G, Memon Farhan
Email(s):
rupali.kote@pravara.in
DOI:
10.52711/2349-2988.2025.00028 
Address:
Kote Rupali B*, Wakchaure Rutuja K, Uchade Komal K, Lokhande Poonam G, Memon Farhan
Department of Pharmaceutics, Pravara Rural Education Society's Institute of Pharmacy, Loni.
*Corresponding Author
Published In:
Volume - 17,
Issue - 3,
Year - 2025
ABSTRACT:
Drug–drug interactions (DDIs) represent a significant clinical challenge, especially in pediatric populations, where multiple drug prescriptions are common. DDIs can alter drug efficacy or toxicity, leading to adverse outcomes, including hospitalization and increased mortality rates. This observational study aimed to assess potential DDIs in pediatric prescriptions at Sadguru Clinic, Zarekati Taluka, Sangamner District, Ahmednagar, using a drug interaction checker. The study focused on pediatric patients prescribed more than two medications, including Advent 228.5 (Amoxicillin and Clavulanic Acid), Maxtra (Chlorpheniramine Maleate and Phenylephrine), Fevfast (Mefenamic Acid and Paracetamol), and Mucolite (Ambroxol). A total of 16 potential interactions were identified, categorized as minor, moderate, or major. Interactions between Amoxicillin and Chlorpheniramine were found to be minor, while combinations of Chlorpheniramine with Phenylephrine, Mefenamic Acid, and Paracetamol were categorized as moderate. The study emphasizes the importance of carefully monitoring drug combinations, particularly in pediatric patients, to minimize potential risks. The findings highlight the need for systematic use of drug interaction software in clinical settings to ensure safer drug prescribing practices. Awareness of potential DDIs and their management could significantly improve patient safety and therapeutic outcomes, reducing medication-related complications in pediatric care.
Cite this article:
Kote Rupali B, Wakchaure Rutuja K, Uchade Komal K, Lokhande Poonam G, Memon Farhan. Study of Potential Drug–Drug Interactions in Pediatric Prescriptions: A Hospital-Based Analysis. Research Journal of Science and Technology. 2025; 17(3):207-0. doi: 10.52711/2349-2988.2025.00028
Cite(Electronic):
Kote Rupali B, Wakchaure Rutuja K, Uchade Komal K, Lokhande Poonam G, Memon Farhan. Study of Potential Drug–Drug Interactions in Pediatric Prescriptions: A Hospital-Based Analysis. Research Journal of Science and Technology. 2025; 17(3):207-0. doi: 10.52711/2349-2988.2025.00028 Available on: https://rjstonline.com/AbstractView.aspx?PID=2025-17-3-2
REFERENCE:
1. Sharma A, Kumar D, Verma P, et al. Drug interactions in pediatric patients: A systematic review. Pediatr Drugs. 2024; 26(1): 1-15.
2. Patel AB, Patel KA, Chaturvedi S, et al. Drug-drug interactions in hospitalized patients: A prevalence study in a tertiary care hospital. Indian J Pharmacol. 2023; 55(5): 335-342.
3. Singh M, Gupta P, Sharma A, et al. Clinical implications of drug-drug interactions in the elderly: A hospital-based study. J Clin Pharmacol. 2023; 63(4): 500-507.
4. Shukla P, Misra S, Pathak A, et al. Identification and management of drug interactions in a geriatric population at a teaching hospital in India. Aging Dis. 2023; 14(2): 325-330.
5. Bansal P, Yadav AK, Meena M, et al. A retrospective study of adverse drug reactions in hospitalized pediatric patients. J Pediatr Pharmacol Ther. 2022; 27(3): 215-220.
6. Aggarwal A, Singh P, Agarwal S, et al. A comprehensive review of drug-drug interactions in clinical practice and their impact on patient safety. Int J Clin Pharm. 2023; 45(6): 871-879.
7. Khan F, Kumar P, Mehta P, et al. Potential drug interactions and their clinical consequences in a tertiary care hospital: A prospective analysis. Br J Clin Pharmacol. 2022; 88(4): 442-449.
8. Singh R, Aggarwal M, Prakash A, et al. Pharmacological management of drug-drug interactions in hospitalized patients: A prospective cohort study. Eur J Clin Pharmacol. 2023; 79(8): 1157-1163.
9. Shinde GS, Jadhav RS, Godge RK, Kote RB, et al. RP-HPLC method development and validation of lamivudine, zidovudine, and nevirapine in bulk and dosage form using UV detector. Res J Pharm Technol. 2024; 17(3): 1567-1573.
10. Shinde GS, Jadhav R, Vikhe D. Development and evaluation of herbal fast disintegrating tablet of Achyranthes aspera Linn root extract. Asian J Pharm. 2024; 18(2): 112-118
11. Verma R, Misra S, Agarwal P, et al. A comprehensive study of drug-drug interactions in pediatric and adult patients: An observational study in a tertiary care setting. Clin Pharmacol Ther. 2023; 102(1): 89-95.